by Matthew Shinkle | Oct 24, 2025 | Uncategorized
The FDA approved belantamab mafodotin-blmf in combination with bortezomib and dexamethasone for the treatment of certain adults with relapsed or refractory multiple myeloma.This indication of belantamab mafodotin-blmf (Blenrep, GSK) applies to adults who have received...
by MM360 Staff | Oct 24, 2025 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by MM360 Staff | Oct 24, 2025 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
by MM360 Staff | Oct 24, 2025 | Uncategorized
Source: CURE articles Post Content Read More
by MM360 Staff | Oct 24, 2025 | Uncategorized
Source: CURE articles Post Content Read More